Canadian Neuromuscular Clinical Trial Database

The Canadian Neuromuscular Clinical Trial Database has been created as an initiative of the NMD4C Clinical Trial Network in collaboration with Canadian neuromuscular clinical trial site teams to provide a comprehensive and reliable landscape of Canadian neuromuscular clinical trials. Monthly updates are provided by clinical research coordinators working at Canadian trial sites, ensuring the most current information is always available.

This database addresses the need for

  • Accurate and up-to-date information: our database provides reliable details about recruiting and not yet recruiting neuromuscular clinical trials, including clinical trial site locations and contact information.
  • Collaboration: our database enables investigators to identify other sites conducting the same trial at different locations, fostering collaboration to address challenges and share best practices.
  • Streamlined patient referral: our database can be used as a tool to facilitate patient referral to appropriate clinical trials and/or clinical sites.
clinical-trial_web

Explore the Clinical Trial Database

Filters

Disease/ConditionTitleSponsor and TreatmentPediatric/AdultSiteLocationRecruitment statusPrincipal InvestigatorContact
gMGRegistry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)Alexion PharmaceuticalsAdultLondon Health Sciences CentreLondon/ONEnrolling by invitation
IIMA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease (RESOLUTION)Allogene - ALLO-329AdultHôpital Maisonneuve-RosemontMontreal, QCRecruitingNicolas RichardOlivier Cormier
CDMSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy (REACH CDM X)AMO Pharma Limited - TideglusibPediatricChildren's Hospital London Health Sciences Centre (LHSC)London, ONEnrolling by invitationCraig CampbellRhiannon Hicks
CMSMulticenter, multinational, natural history study in participants with congenital myasthenic syndromes due to mutations in DOK7, MUSK,AGRN, or LRP4ArgenxPediatricChildren's Hospital of Eastern Ontario (CHEO)Ottawa, ONRecruitingHanns LochmüllerPrachi Inamdar
CIDPA Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy
and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults
with Chronic Inflammatory Demyelinating Polyneuropathy
Argenx - EmpasiprubartAdultGP Research Inc.Montreal, QCNot yet recruitingMaxime BérubéVincent Etten
gMGEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis (ADAPT Jr)Argenx - EfgartigimodPediatricBritish Columbia Children's HospitalVancouver, BCNot yet recruitingKathryn SelbyRitu Ratan
MGEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis (ADAPT Jr)
Pharmacokinetics, Pharmacodynamics, Safety, and
Activity of Efgartigimod in Children From 2 to
Less Than 18 Years of Age With Generalized
Myasthenia Gravis
Argenx - EfgartigimodPediatricAlberta's Children HospitalCalgary, ABRecruitingJean MahIsrat Yasmeen
gMGA Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Argenx - EfgartigimodPediatricBritish Columbia Children's HospitalVancouver, BCRecruitingKathryn SelbyRitu Ratan
gMGA Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia GravisArgenx - EfgartigimodPediatricChildren's Hospital of Eastern Ontario (CHEO)Ottawa, ONRecruitingHugh McMillanPrachi Inamdar
FSHDStudy of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1Arrowhead - ARO-DUX4Adult and PediatricHeritage Medical Research Clinic (HMRC)Calgary, ABRecruitingLawrence KorngutCarissa Wong
FSHDStudy of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1Arrowhead - ARO-DUX4AdultMcGill University Health Centre - CIMMontreal, QCNot yet recruitingAngela GengeMaria Gobbo
FSHDStudy of ARO-DUX4 in Adult Patients with Fascioscapulohumeral Muscular Dystrophy Type 1Arrowhead - ARO-DUX4AdultUniversity of Alberta*Edmonton, ABRecruitingCecile Phan
DM1A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1) Arthrex - ATX-01AdultCIUSSS du Saguenay-Lac-Saint-JeanSaguenay, QCRecruitingJean-Denis BrissonValerie Harvey
XLMTMA Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy.Astellas - ASP2957PediatricThe Hospital for Sick Children (SickKids)Toronto, ONRecruitingHernan GonorazkyAlireza Tavakoli
ATTRMaesTTRo: A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis (D8450R00003)Astra ZenecaAdultVancouver General HospitalVancouver, BCRecruitingMichelle MezeiDeborah Kraus
ATTRMaesTTRo: A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis (D8450R00003)Astra ZenecaAdultCentre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)Montreal, QCNot yet recruitingGeneviève MatteAmélie Bujold
IIMA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) (JASMINE)Astra Zeneca - AnifrolumabAdultJewish General HospitalMontreal, QCRecruitingMarie HudsonMelanie Banina
FSHDA Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD (FORTITUDE-3)Avidity - AOC 1020 (Del-brax)Adult and PediatricHeritage Medical Research Clinic (HMRC)Calgary, ABRecruitingLawrence KorngutCarissa Wong
FSHDA Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)Avidity - AOC-1020 (Del-brax)AdultGP Research Inc.Montreal, QCRecruitingAngela GengeVincent Etten
FSHDA Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD (FORTITUDE-3)Avidity - AOC-1020 (Del-brax)Adult and PediatricUniversity of Alberta*Edmonton, ABNot yet recruiting
FSHDA Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD (FORTITUDE-3)Avidity - AOC 1020 (Del-brax)AdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingHanns LochmüllerJessica MacGregor
FAA Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldBiogen-OmaveloxolonePediatricCHU de QuébecQuebec City, QCRecruitingNicolas ChrestianDavy Eng
FAA Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldBiogen-OmaveloxolonePediatricMcGill University Health Centre - Glen SiteMontreal, QCRecruitingMaryam OskouiMbaye Ndiaye
gMGInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisCartesian - Descartes-08AdultToronto General Hospital*Toronto, ONRecruiting
DM/IMNMPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)Chugai - RAY121AdultCentre de rheumatologie de l'Est du Québec*Rimouski, QCRecruiting
DM/IMNMPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)Chugai - RAY121AdultDIEX Recherche*Sherbrooke, QCRecruiting
DM/IMNMPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)Chugai - RAY121AdultUniversity of Alberta*Edmonton, ABRecruiting
DM/IMNMPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)Chugai - RAY121AdultMcGill University - Montreal Neurological Institute/Hospital (MNI)Montreal, QCRecruitingErin O'FerrallNM research team
gMGEfgartigimod in IVIG Dependent Myasthenia Gravis PatientsClinique Neuro-Outaouais - EfgartigimodAdultClinique Neuro-OutaouaisGatineau, QCRecruitingFrançois Henri JacquesIbrahim Sangare
DM1A Phase 1 Open-Label Trial to Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of DT-818Design Therapeutics - DT-818AdultBiopharma ServicesToronto, ONRecruitingSukriti Malla
MMNA PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH MULTIFOCAL MOTOR NEUROPATHY (MOMENTUM)Dianthus Therapeutics - DNTH103AdultGP Research Inc.Montreal, QCRecruitingAngela GengeVincent Etten
DM1Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Dyne - DYNE101-DM1-301AdultCIUSSS du Saguenay-Lac-Saint-JeanSaguenay, QCNot yet recruitingJean-Denis BrissonValerie Harvey
gMGEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants with Generalized Myasthenia Gravis (MyClad)EMD Serono- Oral CladribineAdultToronto General Hospital*Toronto, ONNot yet recruitingVera BrilLubna Daniyal (416-340-3898)
DM1Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)Hanns LochmüllerPediatricChildren's Hospital of Eastern Ontario (CHEO)Ottawa, ONRecruitingHanns LochmüllerTamara Burgess
SMAA Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy (PUPFISH)Hoffmann-La Roche - RisdiplamPediatricChildren's Hospital of Eastern Ontario (CHEO)Ottawa, ONRecruitingHugh McMillanPrachi Inamdar
DMDEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)Italfarmaco - GivinostatPediatricBritish Columbia Children's HospitalVancouver, BCRecruitingKathryn SelbyGabe Massarotto
DMDEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)Italfarmaco - GivinostatPediatricChildren's Hospital of Eastern Ontario (CHEO)Ottawa, ONRecruitingHugh McMillanHaifa Kourdi
DMDEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)Italfarmaco - GivinostatPediatricHolland Bloorview Kids Rehabilitation HospitalToronto, ONRecruitingLaura McAdamOlivia Mastracci
DMDEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)Italfarmaco - GivinostatPediatricChildren's Hospital London Health Sciences Centre (LHSC)London, ONRecruitingCraig CampbellRhiannon Hicks
gMGA Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisJanssen Research & Development, LLC - NipocalimabAdultOttawa Hospital Research Institute (OHRI)Ottawa, ONNot yet recruitingAriel BreinerIsabel Horton
gMGA Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisJanssen Research & Development, LLC - NipocalimabAdultToronto General Hospital*Toronto, ONRecruiting
CIDPPhase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Janssen Research & Development, LLC - NipocalimabAdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingAriel BreinerIsabel Horton
SBMAUnderstanding the prevalence, clinical features, and genetics of spinal-bulbar muscular atrophy (SBMA) in people of Indigenous descentKennedy Disease AssociationAdultHeritage Medical Research Clinic (HMRC)Calgary, ABRecruitingGerald Pfeffer
SBMAUnderstanding the prevalence, clinical features, and genetics of spinal-bulbar muscular atrophy (SBMA) in people of Indigenous descentKennedy Disease AssociationAdultUniversity of Alberta*Edmonton, ABRecruitingWendy Johnston
SBMAUnderstanding the prevalence, clinical features, and genetics of spinal-bulbar muscular atrophy (SBMA) in people of Indigenous descentKennedy Disease AssociationAdultUniversity of SaskatchewanSaskatoon, SKRecruitingKerri SchellenbergJoanne Boyer
IIMA Study of KITE-363 in Participants With Refractory Autoimmune DiseasesKite - KITE-363AdultJewish General HospitalMontreal, QCRecruitingMarie HudsonMelanie Banina
IIMA Study of KITE-363 in Participants With Refractory Autoimmune DiseasesKite - KITE-363AdultOttawa Hospital, General CampusOttawa, ONRecruitingMichael KennahDanielle Tardiff
FAGene Therapy for Cardiomyopathy Associated With Friedreich's AtaxiaLexeo Therapeutics - LX2006 (AAVrh.10hFXN)Adult and PediatricCentre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)Montreal, QCRecruitingAntoine DuquetteMartine Comeau
FAFriedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study (UNIFAI)Natural History StudyAdult and PediatricCentre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)Montreal, QCRecruitingAntoine DuquetteMartine Comeau
CMSMulticenter, multinational, natural history study in participants with
congenital myasthenic syndromes due to mutations in DOK7,
MUSK, AGRN, or LRP4
Natural History StudyAdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingHanns LochmüllerMahsa Haghighi
CMTA First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1ANovartis - EDK060AdultCHU SherbrookeSherbrooke, QCRecruitingMarie-Fance RiouxCaroline Cayer
CMTA First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1ANovartis - EDK060AdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingAlberto AlemanKathryn Beaudry
CMTA First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1ANovartis - EDK060AdultMcGill University - Montreal Neurological Institute/Hospital (MNI)Montreal, QCRecruitingRami MassieNM research team
gMGA Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)Novartis - RemibrutinibAdultLondon Health Sciences CentreLondon/ONEnrolling by invitation
MGA Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)Novartis - RemibrutinibAdultCHU de QuébecQuebec City, QCRecruitingAnnie DionAlexandra Simard
gMGA randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phaseNovartis - RemibrutinibAdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingAriel BreinerIsabel Horton
DMDNS-050/​NCNP-03 in Boys With DMD (Meteor50)NS Pharma - NS-050/​NCNP-03PediatricAlberta's Children HospitalCalgary, ABNot yet recruitingJean MahJulie Dao
DMDNS-050/​NCNP-03 in Boys With DMD (Meteor50)NS Pharma - NS-050/​NCNP-03PediatricBritish Columbia Children's HospitalVancouver, BCRecruitingKathryn SelbyGabe Massarotto
DMDNS-050/​NCNP-03 in Boys With DMD (Meteor50)NS Pharma - NS-050/​NCNP-03PediatricChildren's Hospital London Health Sciences Centre (LHSC)London, ONRecruitingCraig CampbellRhiannon Hicks
DMDA phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 (Brogidirsen) in boys with Duchenne muscular dystrophy (DMD)NS Pharma - NS-089/​NCNP-02-201PediatricAlberta's Children HospitalCalgary, ABNot yet recruitingJean MahJulie Dao
DMDA phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 (Brogidirsen) in boys with Duchenne muscular dystrophy (DMD)NS Pharma - NS-089/​NCNP-02-201PediatricBritish Columbia Children's HospitalVancouver, BCRecruitingKathryn SelbyGabe Massarotto
DMDA phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 (Brogidirsen) in boys with Duchenne muscular dystrophy (DMD)NS Pharma - NS-089/​NCNP-02-201PediatricChildren's Hospital London Health Sciences Centre (LHSC)London, ONRecruitingCraig CampbellRhiannon Hicks
DM1A Clinical Study of PGN-EDODM1 in People with Myotonic Dystrophy Type 1PepGen - PGN-EDODM1Adult and PediatricHeritage Medical Research Clinic (HMRC)Calgary, ABRecruitingGerald PfefferJanet Petrillo
DM1A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of PGN-EDODM1 in Adult Participants with Myotonic Dystrophy Type 1 (FREEDOM2-DM1)PepGen - PGN-EDODM1AdultCIUSSS du Saguenay-Lac-Saint-JeanSaguenay, QCRecruitingJean-Denis BrissonValerie Harvey
DM1A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of PGN-EDODM1 in Adult Participants with Myotonic Dystrophy Type 1 (FREEDOM2-DM1)PepGen - PGN-EDODM1AdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingHanns LochmüllerJessica MacGregor
DM1An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants with Myotonic Dystrophy Type 1PepGen - PGN-EDODM1AdultCIUSSS du Saguenay-Lac-Saint-JeanSaguenay, QCRecruitingJean-Denis BrissonValerie Harvey
DM1A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM2-DM1)PepGen - PGN-EDODM1AdultMcGill University - Montreal Neurological Institute/Hospital (MNI)Montreal, QCRecruitingErin O'FerrallNM research team
DMDA Phase 1/2 Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD)REGENXBIO Inc. - RGX-202 (AAV8.Spc5-12.microdystrophin)PediatricChildren's Hospital London Health Sciences Centre (LHSC)London, ONRecruitingCraig CampbellRhiannon Hicks
gMGA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)RemeGen Co - TelitaciceptAdultLondon Health Sciences CentreLondon/ONEnrolling by invitation
SMAA Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label ExtensionResearch Institute- McGill University Health CentrePediatricAlberta's Children HospitalCalgary, ABRecruitingJean MahJulie Dao
SMAA Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label ExtensionResearch Institute- McGill University Health CentrePediatricBritish Columbia Children's HospitalVancouver, BCRecruitingKathryn SelbyNela Martic
SMAA Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label ExtensionResearch Institute- McGill University Health CentrePediatricMcGill University Health Centre - Glen SiteMontreal, QCRecruitingMaryam OskouiMbaye Ndiaye
SMAA Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label ExtensionResearch Institute- McGill University Health CentrePediatricIWK*Halifax, NSRecruitingJordan SherikoSara Drisdelle
SMAA Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label ExtensionResearch Institute- McGill University Health CentrePediatricThe Hospital for Sick Children (SickKids)Toronto, ONRecruitingHernan GonorazkyAna Stosic
CIDPA Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkSanofi - RiliprubartAdultCHU de QuébecQuebec City, QCRecruitingAnnie DionAlexandra Simard
CIDPA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (VITALIZE)Sanofi - RiliprubartAdultMcGill University - Montreal Neurological Institute/Hospital (MNI)Montreal, QCRecruitingRami MassieNM research team
CIDPA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Sanofi - RiliprubartAdultCHU de QuébecQuebec City, QCRecruitingAnnie DionAlexandra Simard
DM1A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1 (BrAAVe)Sanofi - SAR446268AdultMcGill University - Montreal Neurological Institute/Hospital (MNI)Montreal, QCRecruitingErin O'FerrallShaghayegh Najafipashaki
DMDA Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD PatientsSatellos - SAT-3247PediatricChildren's Hospital of Eastern Ontario (CHEO)Ottawa, ONRecruitingHugh McMillanEmilie Hill-Smith
DMDA Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)Solid Biosciences Inc. - SGT-003PediatricBritish Columbia Children's HospitalVancouver, BCRecruitingKathryn SelbyNela Martic
CIDPA Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (CASCA)Takeda- TAK411AdultToronto General Hospital*Toronto, ONNot yet recruitingVera Bril
DM1Review of Patients with Congenital Myotonic Dystrophy type 1The Hospital for Sick Children (SickKids)PediatricThe Hospital for Sick Children (SickKids)Toronto, ONRecruitingHernan GonorazkyMagdalena Lovaglio
SMAReview of Treated patients with Spinal Muscular Atrophy The Hospital for Sick Children (SickKids)PediatricThe Hospital for Sick Children (SickKids)Toronto, ONRecruitingHernan GonorazkyMagdalena Lovaglio
DMDThe Expanded Duchenne Muscular Dystrophy (DMD) Natural History Study: Longitudinal Study of the Relationship Between Impairment, Activity Limitation, Participation and Quality of Life (eDNHS)UC Davis / SareptaPediatricAlberta's Children HospitalCalgary, ABRecruitingJean MahJulie Dao
oMGA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PARTICIPANTS WITH OCULAR MYASTHENIA GRAVISUCB - RozanolixizumabAdultGP Research Inc.Montreal, QCNot yet recruitingAngela GengeVincent Etten
gMGSeronegative Myasthenia Gravis - Efgartigimod IVUniversity Health Network, Toronto - Efgartigimod IVAdultToronto General Hospital*Toronto, ONRecruitingVera BrilEduardo Ng
FSHDMotor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) (MOVE FSHD)University of Kansas Medical CenterAdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingHanns LochmüllerJessica MacGregor
FSHDMotor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) (MOVE FSHD)University of Kansas Medical CenterAdult and PediatricHeritage Medical Research Clinic (HMRC)Calgary, ABRecruitingLawrence KorngutCarissa Wong/Janet Petrillo
DM1A Phase 1/​2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (Galileo)Vertex - VX-670AdultCHU de QuébecQuebec City, QCRecruitingAnnie DionAlexandra Simard
DM1A Phase 1/​2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (Galileo)Vertex - VX-670AdultOttawa Hospital Research Institute (OHRI)Ottawa, ONRecruitingHanns LochmüllerKathryn Beaudry
DM1A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IVertex - VX-670AdultMcGill University - Montreal Neurological Institute/Hospital (MNI)Montreal, QCEnrolling by InvitationAngela GengeNM research team
DM1A Phase 1/​2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (Galileo)Vertex - VX‑670AdultCIUSSS du Saguenay-Lac-Saint-JeanSaguenay, QCRecruitingJean-Denis BrissonValerie Harvey
gMGA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Vor - TelitaciceptAdultToronto General Hospital*Toronto, ONNot yet recruiting

*Information from ClinicalTrials.gov